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Abstract
Complex regional pain syndrome (CRPS) is a pain condition that usually affects a single limb, 
often following an injury. The underlying pathophysiology seems to be complex and probably 
varies between patients. Clinical diagnosis is based on internationally agreed-upon criteria, which 
consider the reported symptoms, presence of signs and exclusion of alternative causes. Research 
into CRPS biomarkers to support patient stratification and improve diagnostic certainty is an 
important scientific focus, and recent progress in this area provides an opportunity for an up-to-
date topical review of measurable disease-predictive, diagnostic and prognostic parameters. 
Clinical and biochemical attributes of CRPS that may aid diagnosis and determination of 
appropriate treatment are delineated. Findings that predict the development of CRPS and support 
the diagnosis include trauma-related factors, neurocognitive peculiarities, psychological markers, 
and local and systemic changes that indicate activation of the immune system. Analysis of 
signatures of non-coding microRNAs that could predict the treatment response represents a new 
line of research. Results from the past 5 years of CRPS research indicate that a single marker for 
CRPS will probably never be found; however, a range of biomarkers might assist in clinical 
diagnosis and guide prognosis and treatment.
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Professor Roberto Perez (1968–2017) passed away shortly after this manuscript was initially 
submitted. The remaining authors dedicate this Review to him as a tribute to a good friend, 
brilliant scientist, outstanding teacher and true pioneer of CRPS research.
Complex regional pain syndrome (CRPS) is a persistent pain condition that often results 
from an injury, and is characterized by a variable combination of pain and hyperalgesia, as 
well as vegetative, sensory, motor and trophic symptoms, in the affected limb. By definition, 
these symptoms can no longer be explained by the initial event. In chronic CRPS, signs of 
CNS reorganization such as dystonia, body perception disturbances or sensory deficits that 
follow a central pattern are evident1.
Chronic pain in general is a diagnostic and therapeutic challenge, and the management of 
CRPS is particularly demanding. As in phantom limb pain, treatment must address both the 
loss of limb function and highintensity pain. If treatment of one or both of these aspects 
fails, lifelong suffering and disability can result. However, the outcomes of treatment can be 
good if CRPS is recognized early2, underlining the necessity to search for biomarkers or 
phenotypic characteristics that facilitate prevention, early diagnosis or treatment response. 
Substantial scientific progress in recent years has| identified posttraumatic inflammation as a 
major component of acute CRPS3, which might enable targeted treatment with anti-
inflammatory agents.
Here, we provide an uptodate narrative Review of the latest scientific achievements in CRPS 
research, focusing on biomarkers for diagnosis, treatment and clinical course prediction. 
Considering the stage of biomarker research in CRPS, and using a broad definition of what 
can be considered a ‘biomarker’ or a ‘phenotypic characteristic’ in both a clinical and a 
biological sense, we thought that an integrative approach was warranted, allowing the 
inclusion of studies with less powerful designs than are usually included in systematic 
reviews or metaanalyses. A true systematic approach was deemed unfeasible because 
emerging evidence from exploratory studies would receive insufficient attention (BOX 1).
What do we currently know about CRPS?
CRPS seems to be a human disease. Rodent models provide valuable insights into different 
aspects of the pathophysiology of acute posttraumatic pain and inflammation, but these 
models do not reproduce all the symptoms that patients experience, especially in cases of 
CRPS that last for months or years. Although we have made considerable progress in 
understanding CRPS, the disease is still defined clinically and is diagnosed using clinical 
criteria.
The criteria currently endorsed by the International Association for the Study of Pain, which 
have been validated against several neuropathic pain conditions, encompass the reported 
symptoms and the presence of signs in four different clinical categories, in the absence of 
any other explanation for the complaints4. These clinical categories are as follows: sensory 
symptoms; vasomotor differences between affected and unaffected limbs; sudomotor 
differences or the presence of limb oedema; and a traumarelated motor disorder that includes 
weakness, tremor or dystonia and/or characteristic trophic changes of skin, hair and nail 
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growth. The diagnosis of CRPS requires a history of symptoms in at least three of the four 
categories and the presence of signs in two of the four categories at the time of consultation. 
The presence of sensory symptoms alone cannot sufficiently differentiate CRPS from other 
neuropathic pain disorders because pain, hyperalgesia and sensory loss are common 
characteristics of these conditions. The diagnostic criteria are not perfect, and the specificity 
is only about 70% against neuropathic pain disorders4. Furthermore, variable stringency in 
the application of the clinical diagnostic criteria might partially explain apparent disease 
variability: estimates of CRPS incidence after limb trauma depend on how rigorously the 
diagnostic criteria are applied5.
CRPS has traditionally been differentiated into two clinical subtypes. CRPS that develops 
after major nerve damage is labelled CRPS type II, and the remaining cases are termed 
CRPS type I. The latter subtype is much more common than the former4. A recent study 
suggested two further subtypes: ‘warm’ CRPS and ‘cold’ CRPS. The warm subtype is 
characterized by a warm, red, oedematous and sweaty extremity, whereas the cold type is 
typically indicated by a cold, blue, less oedematous extremity6.
The pathophysiology of CRPS is still controversial, but the latest research suggests the 
following scenario. Most often, the initial event is peripheral limb trauma. Posttraumatic 
inflammation is a normal physiological response, but the exaggerated inflammation in CRPS 
leads to persistent oedema, vasodilation, temperature changes and probably hyperhidrosis 
via release of neuropeptides. Simultaneously, inflammatory mediators (for example, 
cytokines), growth factors, catecholamines and autoantibodies contribute to trophic changes 
(for example, activation of keratinocytes, fibroblasts or osteocytes) and sensitize peripheral 
nociceptors, inducing phenomena such as movementrelated pain and heat hyperalgesia. 
Some of these mediators (in particular, growth factors, cytokines and centrally released 
neuropeptides from primary afferents) also sensitize secondorder neurons in the spinal cord, 
which are responsible for both skin and deeptissue hyperalgesia and allodynia. Longterm 
unresolved nociceptive activity and inflammation, probably leading to peripheral nerve 
damage, cause not only loss of function but also brain changes in susceptible patients. 
Related symptoms include nondermatomal sensory deficits, disturbances of body perception, 
neglectlike phenomena and motor symptoms. The motor symptoms might also have a spinal 
pathophysiology, such as aberrant force feedback regulation from Golgi tendon organs 
involving inhibitory interneurons7. This CRPS model is speculative but is supported by 
results from animal experiments8 and investigations of patient tissue and sensorimotor 
function. The pathophysiology of CRPS is reviewed more extensively elsewhere9.
Selecting risk factors and biomarkers
As CRPS can evolve over time (for example, acute CRPS developing into chronic CRPS, or 
warm CRPS turning into cold CRPS), the existence of a single biomarker that is exclusive to 
this condition is unlikely. Therefore, we must look for risk factors that can predict the 
development of CRPS after trauma and for biomarkers that characterize the early and late 
stages of CRPS, enabling prediction of treatment outcome. As biomarker research in chronic 
pain in general is still in its infancy, we use the term ‘biomarker’ in a broad sense, in 
accordance with the following definition proposed by the Biomarkers Definitions Working 
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Group10: “any measurement reflecting an interaction between a biological system and a 
potential hazard, which may be chemical, physical, or biological. The measured response 
may be functional and physiological, biochemical at the cellular level, or a molecular 
interaction.”
For the purposes of this Review, our definition of risk factors and biomarkers encompasses 
characteristics that have been measured longitudinally and are predictive of CRPS onset or 
treatment response, as well as features that differentiate between affected and unaffected 
limbs and/or between CRPS and adequate pain control groups. Comparisons of patient 
parameters with healthy individuals alone were excluded because the results might not be 
sufficiently specific for CRPS.
One exception to these rules is our decision to discuss microRNAs (miRNAs) in the blood. 
Efforts are underway by international consortia, such as ncRNAPain, to make miRNA data 
available for a large number of patients with CRPS. These miRNA studies have the potential 
to identify posttranslational factors that might be used in the future to determine whether a 
given incident of trauma will cause CRPS and to predict which cases of CRPS will be cured 
and which will become chronic. However, use of the current technology to compare miRNA 
profiles between CRPS and other chronic pain disorders is not yet a viable approach because 
of the substantial overlap in pain signalling pathways, as well as the costs of the tests. We 
designate these molecular signatures for CRPS as ‘emerging biomarkers’ because of the 
strong promise that they hold.
Risk factors for CRPS after trauma
Demographic and trauma-related risk factors.
Evidence regarding demographic and traumarelated risk factors came from a prospective 
inception cohort involving 596 patients, each of whom had a single fracture5. Analysis of 
these factors showed that ankle fracture, fracture dislocation and an intraarticular fracture 
contributed significantly to the development of CRPS type I (sensitivity 62% and specificity 
70% for the regression model). In addition, the presence of rheumatoid arthritis or 
musculoskeletal comorbidities (back pain and arthrosis) was associated with the 
development of CRPS.
In a prospective cohort study of 477 patients, which evaluated CRPS development after 
distal radius surgery, factors that were associated with the development of CRPS type I 
included highenergy injuries (OR 3.3), severe fractures (OR 3.1) and female sex (OR 2.2)11. 
In a Japanese cohort study, the occurrence of CRPS was reported to be especially high 
following fractures of the distal forearm (OR 2.8)12. Contrary to other reports, this study 
found a low incidence of CRPS following fractures of the leg, with no specific sex 
preference. In addition, in this study, a longer duration of anaesthesia (except for regional 
anaesthesia) was reported to be significantly associated with an elevated incidence of CRPS.
A longitudinal study evaluated the influence of pain during the week after fracture on the 
development of CRPS in 1,549 patients with fracture of carpal bones, the distal radius or 
ulna or both, who were treated conservatively13. Overall, the authors observed a 3.8% 
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incidence of CRPS. In patients with average pain scores of ≥5 over 2 days on an 11-step 
rating scale 5–7 days after the fracture (n = 113), the incidence of CRPS was 46% after 4 
months. A smaller consecutive study of 90 patients with distal radius fracture who were 
treated with closed reduction and casting indicated that women who reported severe pain and 
reduced physical quality of life had an increased likelihood of developing CRPS 4 weeks 
after fracture14. Unfortunately, this study found an unusually high incidence of CRPS 
(>30%), probably owing to the use of diagnostic criteria that were not validated for CRPS, 
which weakens the conclusions.
The role of female sex as a risk factor for CRPS is questionable. Women in general have 
lower pain thresholds than men15, and most chronic pain disorders, including migraine, 
fibromyalgia and low back pain, have a strong female predominance. Furthermore, the 
incidence of limb fracture is significantly higher in middleaged or older women than in 
men16,17.
Taking into account the contradicting results regarding trauma type, affected limb and sex, 
we regard an unusually high level of pain during the week after the trauma as the most 
robust risk factor for CRPS development.
Psychological risk factors.
With respect to psychological risk factors for CRPS, the most robust evidence has come 
from prospective cohort studies. In the aforementioned prospective multicentre cohort study, 
which investigated the development of CRPS type I in 596 adults with single fractures5, 
none of the psychological factors that were analysed — namely, agoraphobia, depression, 
somatization, insufficiency, interpersonal sensitivity, insomnia and life events — predicted 
the development of CRPS type I. In addition, scores on the Symptom Checklist90 fell well 
within the range of the general population. These negative findings do not, however, rule out 
a role for other psychological risk factors that were not tested in this study in the 
development of CRPS.
As a secondbest approach, CRPS cohorts have been compared with patients with other pain 
disorders. Unfortunately, such an approach can only provide associations and cannot prove 
causality. In one such investigation, researchers examined the link between CRPS and 
alexithymia, which is the inability (as a stable personality trait) to identify and describe 
feelings18. People with alexithymia have difficulty distinguishing between emotions and 
bodily sensations. The initial evidence suggested that alexithymia ratings on the Toronto 
Alexithymia Scale were significantly higher in patients with CRPS than in patients with low 
back pain. Pain severity in patients with CRPS correlated significantly with high levels of 
alexithymia (Toronto Alexithymia Scale score 67 compared with a score of 49 in patients 
with low back pain). By contrast, patients with CRPS and patients with low back pain were 
similar in terms of levels of pain, disability, depression, anxiety and kinesiophobia19.
In a recent investigation20, 38% of patients with CRPS (n = 152) had positive scores on the 
PostTraumatic Stress Diagnostic Scale compared with only 10% of nonCRPS controls with 
limb pain (n = 55). The severity score on this rating scale was significantly associated with 
CRPS (sensitivity 75% and specificity 72%). In most of the patients, posttraumatic stress 
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symptoms (related to violence, rape, sexual abuse, severe accidents or diseases) started long 
before the CRPSrelated trauma occurred.
The results of these cohort studies await confirmation in prospective investigations. Such 
investigations should concentrate on individuals who experienced high pain levels shortly 
after the trauma.
Diagnostic features and biomarkers
Neuropsychological biomarkers.
Structural MRI — specifically, voxelbased morphometry — has revealed positive and 
negative correlations between pain intensity and cortical thickness in the dorsal insula, left 
orbitofrontal cortex and cingulate cortex21. In paediatric CRPS, restingstate functional 
connectivity on functional MRI (fMRI) — in particular, the connections with forebrain 
areas, which are related to motor, affective, cognitive and pain inhibitory and modulatory 
processes — seems to be reduced22. These fascinating findings might aid our understanding 
of CRPS pathophysiology. However, they cannot serve as biomarkers because their 
specificity for CRPS has not been shown owing to a lack of adequate pain control groups. 
Our literature search identified only one study that included different pain groups23. This 
study found substantial overlaps in default mode network characteristics between CRPS, 
chronic low back pain and osteoarthritis.
Another investigation used MRI to compare the size of the bloodoxygenleveldependent 
(BOLD) response in the primary somatosensory cortex after vibration stimuli on the affected 
versus unaffected hand in patients with CRPS24. The cortical representation area was larger 
on the unaffected side, probably demonstrating compensatory use of the healthy, painless 
hand. Whether this phenomenon is specific for CRPS or applies to all kinds of hand 
immobilization is currently unknown. For more information about functional imaging in 
CRPS, we refer the reader to reviews that concentrate on this field of research25,26.
A growing body of evidence suggests that disturbances of body representation and body 
perception are key features of the CRPS phenotype. Neglectlike phenomena, distorted body 
image, body dysmorphic features, spatial deficits and impairment of executive function have 
all been reported in CRPS27. Impaired spatial perception has been shown to modulate limb 
temperature28, tactile processing, spontaneous pain and sense of ownership of the hands in 
patients with this condition. Experiments in which perceived midline shifts of the hand were 
altered by the use of prism glasses showed that in patients with CRPS, the temperature of the 
affected hand was modulated by the perceived location of the hands as opposed to their 
actual location or anatomical alignment28. On the basis of clinical tests, these features have 
been linked to dysfunction of the parietal lobe29. However, another investigation 
demonstrated that these body perception disturbances occurred regularly after fracture, 
independently of CRPS30.
We must stress that differences in a value between patients with CRPS and limb pain 
controls are not sufficient to formally identify a biomarker, although such differences 
increase the specificity of the finding for CRPS and can demonstrate phenotypic 
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characteristics. Three studies31–33 that compared patients with CRPS with limb pain controls 
indicated that the findings described above hold some specificity for CRPS or are at least 
more pronounced in CRPS. In the dark, righthanded patients with CRPS had a larger 
leftward shift of their subjective visual midline than did righthanded individuals with limb 
pain and healthy controls, regardless of which hand was involved31. This finding was 
interpreted as augmentation of right hemispheric dominance for spatial tasks in patients with 
CRPS, which leads to exaggerated physiological right hemispatial pseudoneglect. 
Interestingly, reporting of socalled neglectlike phenomena, which have a high incidence in 
CRPS, does not correlate with pain intensity in CRPS as it does in other types of limb pain 
but instead correlates with anxiety, depression, somatization and depersonalization32. 
Viewing bistable images exacerbated pain and sensory disturbances in CRPS, including 
changes in perception of the temperature and weight of the affected limb; this phenomenon 
was not observed in pain controls with rheumatological diseases33.
Psychophysical biomarkers.
Quantitative sensory testing has revealed substantial sensory disturbances in patients with 
CRPS. A study that evaluated patterns of sensory signs in upperlimb CRPS types I and II (n 
= 344) showed that patients with CRPS type I had more sensory gain (heat and pressure 
pain) and less sensory loss (thermal and mechanical detection as well as hypoalgesia to heat 
or pinprick) than did patients with peripheral nerve injury. Patients with CRPS types I and II 
had almost identical somatosensory profiles34. A reduced pressurepain threshold — that is, 
increased pain in response to blunt pressure on muscles of the affected limb — seems to be a 
distinguishing feature of CRPS.
A separate study indicated that pressurepain sensitivity was even higher over the joints of the 
affected extremity35. This finding had high sensitivity and specificity for distinguishing 
patients with CRPS from those with nonCRPS pain and healthy controls. A patient with 
CRPS could be identified with a sensitivity of 82% and a specificity of 94% using a cutoff 
value of 102 kPa for pressurepain thresholds at the proximal interphalangeal joints (mean 
value from five joints) on the affected hand. Thus, notable pressurepain hyperalgesia in the 
affected limb is a consistent finding in CRPS and seems to separate this condition from other 
types of limb pain.
Disturbances of central sensory processing in CRPS are indicated by bilateral impaired 
pairedpulse suppression of somatosensory evoked potentials in patients with this condition 
compared with pain controls36. However, researchers found a considerable overlap between 
the two groups.
A finding that has long been regarded as typical for CRPS is an impaired twopoint 
discrimination threshold. A recent review clarified that this phenomenon also occurs in 
various nonneuropathic pain conditions, including arthritic pain and chronic low back pain 
and, therefore, is not specific for CRPS37.
Blood and serum biomarkers.
Almost all of the potential CRPS serum biomarkers that we discuss in this section indicate 
immune activation. The pathophysiological relevance of these markers can be considered 
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within two broad conceptual frameworks, as outlined in FIG. 1. Both frameworks are 
consistent with the suggestion that early antiinflammatory treatment or limb mobilization 
(which can alleviate inflammation) can reduce the risk of CRPS, whereas inhibition of the 
cleavage of inflammatory mediators (for example, by angiotensinconverting enzyme 
inhibitors or limb immobilization) puts patients at higher risk (reviewed in REFS 9,38). 
Current evidence from suction blister investigations and skin biopsies (see next section), as 
well as older bone scintigraphy investigations, indicates that the early posttraumatic 
inflammatory immune activation in CRPS normalizes by about 6 months. Antiautonomic 
immunoglobulin G (IgG) serum autoantibodies are prevalent in both early and late CRPS 
(FIG. 1).
On the basis on CRPS studies without pain controls, inflammatory and antiinflammatory 
serum cytokines are potential biomarkers for CRPS. However, in two studies, serum 
cytokine levels in patients with CRPS (mostly acute CRPS) did not differ from those in 
patients with fractures or upperlimb pain of other origins39,40 (TABLE 1).
Localized osteoporosis and increased bone turnover are frequent findings in early CRPS, but 
serum markers for these processes have been investigated only in the past few years41. 
Osteoprotegerin, a cytokine receptor that is involved in the regulation of bone turnover, was 
found to be elevated in a study of patients with early CRPS, who were compared with 
patients who had normal healing after limb fracture, patients receiving threephase bone 
scanning for cancer staging, and a historical healthy reference group. The test showed a 
sensitivity of 74% and a specificity of 79%, supporting its potential for development as a 
diagnostic assay (TABLE 1). Interestingly, the study showed no correlation between 
osteoprotegerin concentration and disease duration or any of the CRPS clinical signs; 
however, the number of patients was small.
The recent description of autoantibodies in CRPS is promising for biomarker research. 
Using livecell bioassays, two groups have shown that up to 70% of patients with CRPS have 
antiautonomic IgG autoantibodies in their serum42,43. CRPS is associated with autonomic 
disturbances, and abnormal adrenergic receptor activation has previously been linked to the 
generation of pain, raising the possibility that these antiautonomic antibodies contribute to 
CRPS pathophysiology.
Specific IgG serum autoantibodies that activate β2adrenergic or M2muscarinic receptors 
were first identified in patients with early CRPS42. The effects of these antibodies on live 
cells were blocked by coapplication of synthetic peptides located on the second extracellular 
loops of the receptors. Enzymelinked immunosorbent assays (ELISAs) coated with these 
peptides recognized both autoantibodies with high specificity and sensitivity in the serum 
from patients with CRPS (TABLE 1). Surface binding was confirmed by flow cytometry in 
most preparations. These autoantibodies belonged to the IgG1–IgG3 subclasses, and no 
crossreactivity between them was observed44.
In another study, the effects of serum immunoglobulin derived from patients with long-
standing CRPS were examined in adult rodent cardiomyocytes43. The researchers identified 
antibodies that activated either α1Aadrenergic or muscarinic receptors (TABLE 1); the 
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activating antibodies bound their targets with high affinity. Subsequent flow cytometric and 
spectrofluorimetric analyses suggested the presence of distinct pathways of antibodyinduced 
α1Aadrenergic receptor activation.
The specificity of these autoantibodies for CRPS will need to be confirmed in larger, more 
heterogeneous CRPS and pain control populations. These additional studies are needed to 
clarify whether clinical CRPS phenotypes correspond to the presence of autoantibodies and 
to provide a better estimate of the test performance.
Additional approaches to identifying autoantibodies in CRPS, which can form the basis for 
future test development, include the in vivo passive transfer trauma model and in vitro 
studies on primary dorsal root ganglion neurons. In small studies, rodents that received 
injections of IgG from patients with CRPS displayed significantly increased mechanical 
hyperalgesia and swelling in comparison with animals that received control IgG injections, 
but only in the injured hindpaws45,46. This finding suggests that pathogenic autoantibodies 
develop their activity only in the context of injury, consistent with the post traumatic 
development of CRPS. A similar phenomenon was shown in an in vitro study in which 
incubation with CRPS IgG altered the calcium responses to potassium depolarization in 
primary rodent dorsal root ganglion cells, but only if these cells had been coincubated with 
inflammatory mediators47. The biology underpinning the observed dependence of 
autoantibody activity on injury and inflammation is unknown.
Abnormalities in plasma levels of various amino acids48, antioxidants49 and circulating 
CD14+CD16+ monocytes50 have also been described in CRPS, but unfortunately in studies 
that did not include appropriate pain control groups. Therefore, the utility of these factors as 
biomarkers for CRPS remains to be determined.
Biomarkers from skin biopsy and suction blisters.
Skin biopsies allow the investigation of the affected tissue itself. In a rodent fracture and 
casting CRPS model51, skin immunohistochemistry demonstrated keratinocyte proliferation 
and increased skin mast cell count. Increased production of inflammatory cytokines by 
keratinocytes was related to pain behaviour. These findings prompted an investigation of 
skin biopsies in patients with CRPS52. Skin biopsy samples were collected from the affected 
skin and the contralateral mirror site in 55 patients with CRPS and were immunostained for 
keratinocyte proliferation, mast cell markers, tumour necrosis factor (TNF) and IL6. In the 
early stages of CRPS, keratinocytes were activated in the affected skin, resulting in 
proliferation and epidermal thickening. Furthermore, TNF and IL6 were upregulated in 
about 40% of very acute cases, although these factors were only assessed qualitatively. In 
later CRPS (from 6 months to many years in pain), reduced keratinocyte proliferation was 
found, leading to epidermal thinning in the affected skin, and no differences were found in 
immunostaining of TNF and IL6 between the two sides of the body. Patients with acute 
CRPS also showed increased mast cell accumulation in the affected skin (FIGS. 2,3), a 
finding that is not observed in chronic CRPS52; in a separate investigation, Langerhans cell 
numbers were even reduced in longstanding CRPS53.
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These data fit well with clinical impressions that the unaffected side is usually ‘normal’, and 
that changes in pathophysiology occur during the shift from acute to chronic CRPS (see 
FIG. 3 for the role of keratinocytes). The studies were limited in having no pain control 
group and — more importantly — no normalfracturehealing control group. Thus, the 
diagnostic value of skin biopsies is currently limited. Acute CRPS in particular might show 
some overlap with normal fracture healing. However, in the aforementioned study52, all 
patients, regardless of whether their condition was acute or chronic, met the official 
diagnostic criteria for CRPS, which do not differentiate between different CRPSpathologies. 
Therefore, the results from skin biopsies not only demonstrate objective pathophysiological 
differences between acute and chronic CRPS but might also aid in the choice of treatment in 
the future.
To further address the upregulation of TNF in the skin of patients with CRPS, researchers 
took punch biopsies from three different groups: patients with osteoarthritis or acute 
fractures who were awaiting surgery, and patients with CRPS who had a disease duration of 
~6 months (biopsies were taken from the affected side)40. Quantification of TNF by ELISA 
showed that patients with CRPS had elevated TNF levels in the skin compared with the two 
control groups. These results corroborate the findings discussed above. However, substantial 
overlap in the values between the groups limits the use of skin TNF as a biomarker.
An alternative approach to skin biopsy is the investigation of skin suction blister fluids. Pro-
inflammatory and antiinflammatory cytokines, including the IL1 receptor antagonist protein 
(IL1Ra), IL2, IL6, IL8, IL10, IL12p40, TNF and the chemokines eotaxin, monocyte 
chemotactic protein 1 (MCP1) and macro phage inflammatory protein 1β (MIP1β), were 
analysed in skin blister fluids from patients with CRPS (disease duration <1 year) and 
patients with upperlimb pain of other origin (nonCRPS controls)39. This analysis was 
repeated after 6 months of CRPS treatment. Blister fluid was collected from the affected and 
unaffected sides of the body. Compared with controls, patients with CRPS showed a bilateral 
increase in TNF and MIP1β and a decrease in antiinflammatory IL1Ra protein levels. 
Neither group showed differences between the two sides of the body. Again, the overlap in 
levels of individual cytokines between the groups was high. However, the pattern of changes 
(increase in proinflammatory and decrease in antiinflammatory cytokines; see also Parkitny 
et al.3) seems to be relatively specific for CRPS because it was not present on either side in 
the control group. After 6 months of CRPS treatment, levels of most cytokines in patients 
with CRPS reverted bilaterally to the levels seen in nonCRPS controls. These changes were 
not related to treatment outcome. This unexpected bilaterality could indicate a ‘trait’ or a 
generalized inflammatory reaction, or it might be related to the long suction period, which 
allows systemic substances to enter the fluid, as has been repeatedly shown in 
pharmacokinetic studies.
Small non-coding RNAs (microRNAs) as emerging biomarkers in CRPS.
Circulating miRNAs are providing a novel source of prognostic and diagnostic biomarkers. 
Encoded in the genome, miRNAs are naturally occurring, small noncoding RNA molecules 
of ~22 nucleotides. Complementarity of a 6 bp seed sequence facilitates the binding of a 
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mature miRNA to its target mRNA. An miRNA can negatively regulate gene expression 
either by repressing protein translation or through mRNA degradation54.
Enclosure of miRNAs in membranous vesicles or their association with RNAbinding 
proteins is now known to confer protection from RNases, allowing circulating miRNAs to 
travel long distances without undergoing degradation55. Exosomes are 30–100 nm vesicles 
that carry miRNAs, mRNAs, proteins and lipids, and the composition varies depending on 
the secreting cell56. Horizontal transfer of circulating miRNAs between cells is a novel 
mode of intercellular communication57.
Studies on miRNAs in chronic pain, and particularly CRPS, are still in their infancy. The 
mode of action of miRNAs (they can regulate multiple pathways) renders them promising 
candidates to help explain the pathophysiology of complex diseases. In view of their 
potential, we include research on miRNAs in CRPS in this Review despite the lack of 
studies in large patient populations with adequate controls.
The lack of uniformity in the pathophysiology underlying CRPS led researchers to wonder 
whether circulating miRNAs could aid in patient stratification. In one of the first studies, 
circulating miRNAs were profiled in whole blood from 41 patients with CRPS and 20 
controls58. The researchers found that levels of 18 miRNAs differed significantly between 
patients and controls. The miRNA signatures also enabled patient stratification: on the basis 
of changes in levels of relevant miRNAs, a cluster analysis revealed three different groups. 
One group comprised 60% of the patients with CRPS and none of the controls. The 
remaining 40% of patients with CRPS had more heterogeneous miRNA profiles and were 
clustered together with the control individuals in the other two groups. The patients in the 
first group did not differ clinically from the patients with CRPS in the other groups, 
suggesting that the symptoms that patients with CRPS share, and on which diagnosis is 
based, do not necessarily result from identical molecular mechanisms. When the 60% of 
patients with CRPS were analysed as a group, additional miRNAs and inflammatory 
markers emerged that were not evident in the overall CRPS patient population in the study. 
Thus, the molecular signature of circulating miRNAs can aid identification of additional 
biomarkers that are specific to a subset of patients57.
Exosomes purified from the serum of six patients with CRPS and six healthy controls were 
used to study whether exosomal miRNAs reflect miRNA signatures in whole blood59. 
Interestingly, significant differences in 127 exosomal miRNAs were observed between the 
two groups. Additional studies are needed to investigate factors that influence the packaging 
of specific miRNAs into exosomes in patients with CRPS.
Circulating miRNAs could be an indicator of aberrations in cellular homeostasis that 
underlie disease60, and investigation of the target mRNAs of differentially expressed 
miRNAs might provide important insights into aberrant gene expression that contributes to 
the disease pathology. A 2011 study investigated the mechanistic relevance of miR939 (REF. 
58), which was found to be downregulated 4.3fold in patients with CRPS. Using a variety of 
in vitro molecular and biochemical approaches, the researchers showed that miR939 can 
target several mRNAs encoding various proinflammatory mediators, including IL6, vascular 
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endothelial growth factor, nitric oxide synthase 2 and nuclear factorκB2. This finding 
suggests that miR939 regulates multiple proinflammatory genes, and downregulation of this 
miRNA in patients with CRPS may contribute to an increase in inflammation and pain61. 
This epigenetic research is promising, but the associated workload and costs preclude 
routine testing at the moment.
These results are consistent with a genomewide RNA expression profiling study, in which 
blood from patients with CRPS was examined62. Eighty genes, many of which were 
associated with immunity and defence, were differentially expressed. Most striking was the 
fourfold upregulation of the matrix metalloproteinase 9 (MMP9) gene, as assessed by 
quantitative reverse transcription PCR.
By contrast, in another study, no differences in DNA singlenucleotide polymorphisms 
(SNPs) were found between patients with CRPS and unspecified controls63. A large number 
of SNPs (>200,000) were analysed, but no difference passed the statistical threshold after 
Bonferroni correction. This negative result is not unexpected, because association studies 
with a broad approach require much larger cohorts, and such an effort would be challenging 
for a rare disease such as CRPS.
Markers for progression and treatment
Clinical and psychological biomarkers and clinical characteristics.
A systematic review published in 2014 found evidence that most patients with CRPS 
partially recover within 6–13 months; however, a substantial number of patients with this 
condition experience lasting symptoms, chronic pain and disability64. This paper was 
followed up by a prospective cohort study that included patients with wellcharacterized 
disease. Focusing on important clinical parameters65, the study showed that clinically 
relevant reductions could be observed in the majority of signs and symptoms of CRPS at 1 
year; the greatest improvements were achieved within 6 months. At 12 months, however, 
onequarter of the patients still met the current diagnostic criteria for CRPS, and just 5% 
were symptomfree. Another cohort study involving patients with postfracture CRPS reported 
that none of the patients were symptomfree 12 months after the trauma5.
Data from a prospective study66 suggest that in patients who receive conservative treatment, 
female sex and high levels of baseline pain and disability predict high CRPS severity 12 
months after disease onset. Patients with low painrelated fear had lower levels of disability 
over the 12month period, and baseline anxiety and disability were positively associated with 
pain intensity over 12 months. By contrast, body perception disturbances, depression and 
general stress did not predict outcomes. The relevance of predictors might be treatment-
specific, as a study that evaluated the effects of two physical therapy modalities found no 
indication that painrelated fear mediates outcome67. Limited evidence indicates that 
sympathetic blocks are efficacious for treating CRPS pain, and allodynia and hypoaesthesia 
were reported to be negative predictors for response to this treatment after 7 days68.
To reinforce the conclusions from the aforementioned studies, replication with standardized 
treatment approaches are needed.
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Ketamine is an established treatment for CRPS in some countries, but a subset of patients 
responds poorly to this drug. A proofofconcept study investigated whether expression of 
circulating miRNAs in whole blood from patients with treatmentresistant CRPS was altered 
in response to ketamine therapy69. This analysis identified 14 miRNAs that were 
differentially expressed before and after treatment in both good and poor responders to 
ketamine. Comparison of miRNAs in responders relative to poor responders before 
treatment showed differential expression of 33 miRNAs. In the posttreatment samples, 43 
miRNAs differed between responders and poor responders. These results indicate the 
potential feasibility of using miRNA signatures in the circulation as biomarkers to predict 
treatment response.
Determining the functional relevance of miRNA changes in the circulation is challenging 
because miRNAs can bind to multiple mRNAs through seed sequence complementarity. 
Although several miRNAs were altered in the aforementioned proofofconcept study69, the 
authors focused on miR548d for detailed target validation studies because of its potential 
regulatory role in ketamine metabolism according to bioinformatic predictions. 
Biotransformation of drugs and xenobiotics generally occurs in two stages, termed phase I 
and phase II. The phase I or oxidation–reduction step is primarily mediated by cytochrome 
P450 superfamily enzymes. The UDPglucuronosyltransferases (UDPGTs) are conjugative 
enzymes that mediate phase II metabolism. In phase I, ketamine is metabolized to 
norketamine; both ketamine and norketamine are further metabolized and eliminated by 
phase II enzymes, specifically UDPGTs, through glucuronidation. In vitro studies in a liver 
cell line confirmed that miR548d5p can bind and regulate the UDPGT gene UGT1A1. 
Levels of miR548d5p were 18fold lower in poor responders than in responders to ketamine. 
These results suggest that different levels of miR548d5p lead to differences in UDPGT 
activity between responders and poor responders.
In addition to miR548d5p, a second miRNA, miR34a, was investigated in the context of 
BMI in ketaminetreated patients with CRPS70. On average, the BMI was lower in poor 
responders than in responders. Proopiomelanocortin (POMC)related peptides have an 
important role in the regulation of body weight, appetite and energy expenditure, and 
reduced POMC expression is associated with increased body weight. Ketamine treatment 
did not alter POMC expression, but poor responders had higher levels of POMC mRNA than 
did responders, both before and after treatment. Corticotropinreleasing hormone (CRH; also 
known as corticoliberin) is a key regulator of POMC expression — an effect that is mediated 
by CRH receptor 1 (CRHR1). The researchers found that miR34a, which is a negative 
regulator of CRHR1, was markedly downregulated in poor responders. Poor responders 
showed higher expression of CRHR1 mRNA in whole blood than did responders, indicating 
a regulatory role for miR34a. Pretreatment levels of miR34a correlated positively with BMI 
and with response to ketamine therapy: poor responders had lower BMI and lower 
pretreatment levels of circulating miR34a. These findings indicate a mechanism through 
which miR34a can regulate the CRH– CRHR1–POMC axis and possibly influence BMI. If 
sufficiently powered studies can replicate these findings and define combined cutoff points 
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for miR548d5p, miR34a and BMI, a simple score to predict pain response to prolonged 
infusion of ketamine seems possible, and unnecessary treatment could be avoided.
Conclusions and future directions
Substantial progress has been made in CRPS research in recent years, enabling a better 
understanding of this condition, which is a prerequisite for the identification of risk factors 
and biomarkers for prevention, diagnosis, disease course and treatment. Biomarker research 
in CRPS is far from perfect, however, and most conclusions that can be drawn are still 
tentative.
To encapsulate the biomarker research of the past 5 years, as reported in this Review, we 
present a ‘prototypical’ patient in BOX 2. We are aware that the description of this patient is 
not supported by rigorous analysis of the published results, such as by a systematic review. 
However, even this tentative description would not have been possible a few years ago. The 
fact that specific ‘biomarkers’ can be linked to particular subgroups of patients with CRPS 
indicates divergent causes of pain and other symptoms. Thus, the discovery of specific 
biomarkers, which in turn can result in individualized treatment, is likely to depend on 
reliable subtyping. Accomplishment of this goal will require identification of new molecular 
signatures of CRPS or analysis of various combinations of existing signatures, including 
DNA, RNA and proteins, along with clinical parameters. The biomarkers must be easily 
accessible and testable. This research will not eliminate CRPS, but it holds the promise of 
reducing pain and suffering and facilitating healing in a substantial number of patients.
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• Complex regional pain syndrome (CRPS) is a persistent pain condition that 
often results from an injury and usually affects a single limb.
• An unusually high level of pain during the week after the injury seems to be 
the most robust risk factor for CRPS development.
• Post-traumatic inflammation has been identified as a major component of 
acute CRPS, and growth factors, catecholamines and autoantibodies have also 
been implicated in CRPS pathogenesis.
• A growing body of evidence indicates that disturbances of body 
representation and body perception are key features of the CRPS phenotype.
• Small non-coding RNAs (microRNAs) are emerging as diagnostic and 
prognostic biomarkers for CRPS.
• A single marker for CRPS is unlikely to be found; however, a range of 
biomarkers might assist in clinical diagnosis and guide prognosis and 
treatment.
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Limitations of this Review
A major limitation of this article is that it does not fulfil the formal criteria for a 
systematic review. Although we made every effort to retrieve all relevant studies 
published between 2011 and 2016, this Review must be regarded as reflecting the 
opinions of experts in the field. Our decision not to undertake a systematic 
comprehensive review was based on the following thoughts: first, biomarker research in 
complex regional pain syndrome (CRPS) is in its infancy, and the available studies are 
too small to obtain high-level evidence; second, most of the included studies were either 
cohort or exploratory studies; third, the quality of reporting methods in 
pathophysiological studies varies considerably; and fourth, we wished to report the latest 
scientific achievements and to inspire future CRPS research rather than reporting on 
studies that are lacking and describing the shortcomings of existing studies. The third 
point regarding the quality of reporting methods in existing studies leads us to another 
limitation. The analytical methods and sample preparation protocols that were used in the 
various studies were often laboratory-specific, making cross-study comparisons difficult.
The final limitation is CRPS itself as a topic for a systematic review. The results of CRPS 
research indicate that CRPS is a heterogeneous syndrome with various clinical 
presentations that change over time. Therefore, the emergence of a single biomarker with 
the necessary precision to drive CRPS risk assessment, diagnosis or treatment seems 
unlikely. Hopefully, this Review will inspire research groups to mount coordinated efforts 
to overcome these limitations.
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A prototypical patient with CRPS
By depicting a ‘prototypical’ patient with complex regional pain syndrome (CRPS), the 
figure delineates and summarizes how the biomarkers and risk factors that have been 
discovered in the past 5 years could help to identify patients at risk of CRPS, improve 
diagnosis through specification of PNS-derived and CNS-derived phenotypic 
characteristics and offer the possibility of individualized treatment in the future.
Given the overrepresentation of postmenopausal women among patients with CRPS, our 
patient is a middle-aged woman with a history of rheumatic disease. She sustains a 
complicated fracture, and her pain is still extreme 1 week after the fracture. A diagnosis 
of CRPS is likely if she fulfils the current clinical diagnostic criteria, but alternative 
diseases must still be excluded4. If the patient demonstrates a leftward shift of the body 
midline in the dark and her pain intensifies while she concentrates on bistable images, the 
likelihood of a CRPS diagnosis increases, particularly if the pain substantially worsens 
when mild pressure is applied to the joints of the affected limb distal to the injury site. 
Psychological investigations demonstrate high levels of alexithymia and post-traumatic 
stress. If blood analysis reveals high serum osteoprotegerin levels and autoantibodies 
against autonomic nervous system receptors, the probability of CRPS increases further. 
To enable bespoke treatment, skin biopsies or suction blister examinations are performed. 
If inflammation is present, anti-inflammatory treatment can be initiated. Intravenous 
ketamine for pain control is started only if levels of circulating microRNAs — in 
particular, miR-548d-5p and miR-34a — in the blood predict a favourable response. 
Owing to this patient’s high disability and anxiety at baseline, she must be closely 
followed and her disease-related anxiety must be addressed (for example, in graded 
exposure treatment71).
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Figure 1. Hypothetical conceptual frameworks for CRPS.
a | Schematic representations of acute and persistent complex regional pain syndrome 
(CRPS). Proximally pointing arrows indicate signalling in response to distal excitation, and 
distally pointing arrows indicate descending signals leading to neuropeptide secretion and 
neurogenic inflammation. The depicted events correspond to the time points indicated by 
dashed grey lines in the graphs. b | Framework 1: augmented (neuro) immune activation. 
After injury (arrow), inflammatory mediators are produced by mast cells, sensory nerves, 
keratinocytes and osteocytes (represented by symbols in part a). In acute CRPS, mediator 
production is temporarily increased, triggering augmented post-traumatic clinical signs and 
primary afferent sensitization and leading to segmental spinal cord dorsal horn sensitization 
and sometimes a shift in the cortical representation of the affected limb with abnormal limb 
perception. Mediators and clinical signs normalize by about 6 months. In persistent CRPS, 
local production of inflammatory mediators at the affected limb normalizes and CNS 
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changes now drive the clinical picture. In this framework, CRPS-associated autoantibodies 
might contribute to some clinical signs, such as sweating, but do not explain the main 
symptoms of pain and hypersensitivity. c | Framework 2: autoantibodies. If distal limb 
trauma is sustained during a time window of vulnerability characterized by high 
autoantibody production (solid grey lines), an enhanced trauma-induced inflammatory 
response renders these antibodies locally pathogenic, resulting in augmented post-traumatic 
signs. Autoantibodies might bind to neurons, causing afferent sensitization through changes 
in the transduction or transmission properties of these cells, or to perineural cells, which 
then release pronociceptive molecules (not shown). These autoantibodies are 
noninflammatory; that is, they neither activate complement nor attract immune cells. Acute 
CRPS resolves after cessation of autoantibody production. A small group of patients 
develops persistent CRPS, in which autoantibody production continues at a reduced rate that 
is still sufficient to sustain the clinical phenotype.
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Figure 2. Mast cell accumulation in CRPS.
a | CD117-positive mast cells, which are stained dark red, in skin biopsy samples from the 
affected limb and a corresponding site on the unaffected limb of a patient with complex 
regional pain syndrome (CRPS). b | The number of mast cells per square millimetre in the 
subcutaneous tissue is significantly increased in the affected skin of patients with acute 
CRPS52 (≤6 months after diagnosis).
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Figure 3. The possible role of keratinocytes in CRPS pathophysiology.
In complex regional pain syndrome (CRPS), activation of peptidergic nociceptors not only 
causes pain but also leads to release of neuropeptides (substance P (SP) and calcitonin gene-
related peptide (CGRP)). Both of these peptides activate keratinocytes and promote their 
proliferation. In turn, the keratinocytes secrete cytokines, which sensitize the peptidergic 
nociceptors for forthcoming stimuli. The resulting facilitated release of SP from primary 
afferent neurons leads to activation of mast cells via specific receptors. Mast cells also 
release inflammatory mediators, which sensitize nociceptors and further activate 
keratinocytes. Pain activates the sympathetic nervous system, releasing noradrenaline (NA) 
that also activates keratinocytes. Consequently, a vicious circle might be established. This 
figure is based on the findings of a series of studies on tibia fracture models in rodents and 
research in patients with CRPS. β2-AR, β2-adrenergic receptor; CRLR, calcitonin receptor-
like receptor; GP130, membrane glycoprotein 130; IL-6R, IL-6 receptor; NK1R, neurokinin 
1 receptor (also known as SPR); RAMP1, receptor activity-modifying protein 1; TNF, 
tumour necrosis factor; TNFR, TNF receptor. Figure adapted with permission from REF. 52, 
Elsevier.
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